Asia Business News

Clinical Cell Culture Signs Supply Agreement with CSL Ltd For Key Component of Tissue Harvesting

Thursday September 28 8:37 PM

Perth, Australia, Sept 28, 2006 - (ACN Newswire) - Clinical Cell Culture Ltd (ASX: CCE.AX) today announced that it had entered into a supply agreement with CSL Limited (ASX: CSL.AX) for the supply of Trypsin, a key component of the Company's ReCell(R) tissue harvesting device.

ReCell (R) is a unique medical device that assists plastic, cosmetic, dermatology and burn surgeons in repairing a wide range of skin defects. ReCell (R) is intended for use in patients with injuries of up to 2% of the body surface or 320cmSq.

Under the terms of the agreement, C3 has committed to a minimum quantity of Trypsin from CSL over a 2 year period, resulting in a financial commitment of $1 million.

CEO Bob Atwill said he was delighted that the supply of Trypsin had been secured with CSL, Australia's leading biopharmaceutical company. "This agreement locks in the supply of enhanced formulations of Trypsin and the minimum purchase quantity reflects the anticipated increase in ReCell(R) sales in the next 2 years."

"We have worked with CSL for a number of years and we look forward to developing our relationship in the supply of this key component," said Mr Atwill.

President Asia Pacific CSL Bioplasma Tom Giarla said this agreement will continue our close working partnership and enable us to jointly develop the Trypsin product and technology platform.

About CLINICAL CELL CULTURE LIMITED:

Clinical Cell Culture (C3) is a publicly listed biomedical company that develops and distributes a number of tissue-engineered products for the treatment of wounds and other skin defects. Using proprietary tissue-culture/ collection technology, C3 is able to provide innovative treatment solutions derived from the patients own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.

About CSL LIMITED:

Development, manufacturing and marketing of pharmaceutical and diagnostic products, cell culture media and human plasma fractions.

Contact:

John McGlue
Porter Novelli
Tel: +61 (0) 8 9386 1233
Mob: +61 (0) 417 926 915
 

Source:

CLINICAL CELL CULTURE LIMITED

Copyright (C) 2006 ACN Newswire. All rights reserved.

ABN Newswire

All Stories


Related Quotes
chart All Detailed Quotes
Delayed 20 mins
Quote data provided by Reuters
Top Stories
· GE profit falls 44%, but tops forecasts - AFP Business News, ( Saturday October 17, 2009, 1:16 am)
· US industrial production jumps in September - AFP Business News, ( Saturday October 17, 2009, 12:44 am)
· Fortescue posts quarterly loss - AAP, ( Friday October 16, 2009, 8:53 pm)
· Verve boss defends huge payrise - ABC Business News, ( Friday October 16, 2009, 8:26 pm)
More...

Finance Message Boards
Most recent posts:
AUSTRALIA - ECONOMIC DISASTER LOOMS797
The New Bruce4
Unless we ACT - Our Economy is Doomed!19
WHO GIVES A..... ABOUT DISASTER???????2
GMG (Goodman) Buy or Sell?78
More Finance Boards

Email this Article Email this story - Print this Article  Printer friendly version

Next article:Auzex Resources Commence Molybdenum Trial Mining At Kingsgate
Previous article:China Improves Statistical Methods To Measure Services Sector Growth



Copyright © 2009 Yahoo!7 Pty Limited. All rights reserved.
Advertise with Us - Privacy Policy - Terms of Service.